Amylyx Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA, 02142
Mailing Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA, 02142
Phone
617-682-0917
Fiscal Year End
1231
EIN
464600503
Financial Overview
FY2025
$433.43M
Stockholders' Equity
$-1.53
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
Annual Reports
10-K
March 3, 2026
- Strategic pivot to a revitalized pipeline, led by Avexitide for post-bariatric hypoglycemia (PBH).
- Avexitide is in Phase 3 (LUCIDITY trial) with topline data expected in late 2026 or early 2027.
Insider Trading
STRONG SELL
6 insiders
18 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.